|
PL1696920T3
(pl)
|
2003-12-19 |
2015-03-31 |
Plexxikon Inc |
Związki i sposoby opracowywania modulatorów Ret
|
|
US7498342B2
(en)
*
|
2004-06-17 |
2009-03-03 |
Plexxikon, Inc. |
Compounds modulating c-kit activity
|
|
US7709645B2
(en)
*
|
2004-07-27 |
2010-05-04 |
Sgx Pharmaceuticals, Inc. |
Pyrrolo-pyridine kinase modulators
|
|
US7626021B2
(en)
*
|
2004-07-27 |
2009-12-01 |
Sgx Pharmaceuticals, Inc. |
Fused ring heterocycle kinase modulators
|
|
EP2264033A1
(en)
|
2004-07-27 |
2010-12-22 |
SGX Pharmaceuticals, Inc. |
3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS
|
|
BRPI0513899A
(pt)
|
2004-07-27 |
2008-05-20 |
Sgx Pharmaceuticals Inc |
moduladores de cinase heterocìclica de anel fundido
|
|
ZA200704888B
(en)
*
|
2004-11-22 |
2009-02-25 |
Vertex Pharma |
Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
|
|
CA2608733A1
(en)
*
|
2005-05-17 |
2007-02-01 |
Plexxikon, Inc. |
Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
|
|
DK2395004T3
(en)
*
|
2005-06-22 |
2016-03-21 |
Plexxikon Inc |
Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
|
|
CA2628179A1
(en)
*
|
2005-11-15 |
2007-05-24 |
Vertex Pharmaceuticals Incorporated |
Azaindazoles useful as inhibitors of kinases
|
|
US20130096302A1
(en)
*
|
2005-11-22 |
2013-04-18 |
Hayley Binch |
Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
|
|
US9534001B2
(en)
*
|
2006-03-03 |
2017-01-03 |
Chemetall Gmbh |
Organomagnesium synthesis agent
|
|
US20070286864A1
(en)
*
|
2006-06-09 |
2007-12-13 |
Buck Elizabeth A |
Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
|
|
CL2007002617A1
(es)
*
|
2006-09-11 |
2008-05-16 |
Sanofi Aventis |
Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
|
|
CA2667428A1
(en)
*
|
2006-10-23 |
2008-05-02 |
Sgx Pharmaceuticals, Inc. |
Bicyclic triazoles as protein kinase modulators
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
WO2008080015A2
(en)
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
WO2008079909A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Pyrrolo [2,3-b] pyridines as kinase modulators
|
|
PE20081581A1
(es)
*
|
2006-12-21 |
2008-11-12 |
Plexxikon Inc |
COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
|
|
CN101679436A
(zh)
*
|
2007-04-10 |
2010-03-24 |
Sgx药品公司 |
稠环杂环激酶调节剂
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
KR101156845B1
(ko)
*
|
2007-05-21 |
2012-06-18 |
에스지엑스 파마슈티컬스, 인코포레이티드 |
헤테로시클릭 키나제 조절제
|
|
WO2008156174A1
(ja)
|
2007-06-21 |
2008-12-24 |
Taisho Pharmaceutical Co., Ltd. |
ピラジンアミド化合物
|
|
EP2170884A2
(en)
*
|
2007-06-25 |
2010-04-07 |
Boehringer Ingelheim International GmbH |
Chemical compounds
|
|
US20100190777A1
(en)
|
2007-07-17 |
2010-07-29 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
KR20090031122A
(ko)
*
|
2007-09-21 |
2009-03-25 |
주식회사 중외제약 |
인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물
|
|
KR101261514B1
(ko)
*
|
2008-02-25 |
2013-05-07 |
에프. 호프만-라 로슈 아게 |
피롤로피라진 키나아제 저해제
|
|
CA2716223A1
(en)
*
|
2008-02-25 |
2009-09-03 |
F. Hoffmann-La Roche Ag |
Pyrrolopyrazine kinase inhibitors
|
|
CN101952295B
(zh)
*
|
2008-02-25 |
2013-11-20 |
霍夫曼-拉罗奇有限公司 |
吡咯并吡嗪激酶抑制剂
|
|
WO2009157423A1
(ja)
*
|
2008-06-24 |
2009-12-30 |
財団法人乙卯研究所 |
縮合環を有するオキサゾリジノン誘導体
|
|
JP5702293B2
(ja)
|
2008-11-10 |
2015-04-15 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な化合物
|
|
WO2010059771A1
(en)
*
|
2008-11-20 |
2010-05-27 |
Osi Pharmaceuticals, Inc. |
Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
|
|
BRPI0924084B1
(pt)
|
2008-12-19 |
2021-12-21 |
Vertex Pharmaceuticals Incorporated |
Derivados de pirazina e composição farmacêutica que os compreende
|
|
HUE027598T2
(en)
*
|
2009-04-03 |
2016-10-28 |
Hoffmann La Roche |
Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses
|
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
|
EP2464232B1
(en)
|
2009-08-10 |
2015-10-07 |
Samumed, LLC |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
|
EP2464231A4
(en)
*
|
2009-08-10 |
2013-02-06 |
Samumed Llc |
INDAZOLE AS WNT / B-CATENINE SIGNALING PATHWASHER AND THERAPEUTIC APPLICATIONS THEREOF
|
|
EP2470533A4
(en)
|
2009-08-24 |
2013-01-23 |
Ascepion Pharmaceuticals Inc |
UREA COMPOUNDS CONTAINING A 5,6-BICYCLIC HETEROARYL GROUP
|
|
ES2633317T3
(es)
|
2009-11-06 |
2017-09-20 |
Plexxikon, Inc. |
Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
|
|
SMT201700581T1
(it)
|
2009-12-21 |
2018-01-11 |
Samumed Llc |
1h-pirazolo[3,4-b]piridine e loro usi terapeutici
|
|
MX2012008642A
(es)
*
|
2010-01-27 |
2012-11-23 |
Vertex Pharma |
Inhibidores de cinasas de pirazolopiridinas.
|
|
CN102858769A
(zh)
*
|
2010-01-27 |
2013-01-02 |
沃泰克斯药物股份有限公司 |
吡唑并吡啶激酶抑制剂
|
|
US20120329826A1
(en)
*
|
2010-03-03 |
2012-12-27 |
OSI Pharmaceuticals,. LLC |
Substituted-5-aminopyrrolo/pyrazolopyridines
|
|
EP2569287B1
(en)
|
2010-05-12 |
2014-07-09 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
US9062008B2
(en)
|
2010-05-12 |
2015-06-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8962631B2
(en)
|
2010-05-12 |
2015-02-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
AU2011253025A1
(en)
|
2010-05-12 |
2012-11-29 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2013526538A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
WO2011143422A1
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
2 -aminopyridine derivatives useful as inhibitors of atr kinase
|
|
WO2011143646A1
(en)
|
2010-05-14 |
2011-11-17 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
WO2011163527A1
(en)
*
|
2010-06-23 |
2011-12-29 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
|
|
DE102010049877A1
(de)
|
2010-11-01 |
2012-05-03 |
Merck Patent Gmbh |
7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
|
|
MA34948B1
(fr)
|
2011-02-07 |
2014-03-01 |
Plexxikon Inc |
Composes et procedes de modulation de kinase, et leurs indications
|
|
TWI558702B
(zh)
|
2011-02-21 |
2016-11-21 |
普雷辛肯公司 |
醫藥活性物質的固態形式
|
|
US8791112B2
(en)
|
2011-03-30 |
2014-07-29 |
Arrien Pharmaceuticals Llc |
Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
|
|
WO2012138938A1
(en)
|
2011-04-05 |
2012-10-11 |
Vertex Pharmaceuticals Incorporated |
Aminopyrazine compounds useful as inhibitors of tra kinase
|
|
EP2710003A1
(en)
|
2011-05-16 |
2014-03-26 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
JP2014522818A
(ja)
|
2011-06-22 |
2014-09-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
EP2723745A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
JP2014517079A
(ja)
|
2011-06-22 |
2014-07-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
AU2012308570B2
(en)
|
2011-09-14 |
2016-11-10 |
Samumed, Llc |
Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors
|
|
WO2013049719A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013049720A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
IN2014CN02501A
(enExample)
|
2011-09-30 |
2015-06-26 |
Vertex Pharma |
|
|
MX2014003796A
(es)
|
2011-09-30 |
2015-01-16 |
Vertex Pharma |
Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
|
|
SG10201606774UA
(en)
|
2011-09-30 |
2016-10-28 |
Vertex Pharma |
Processes for making compounds useful as inhibitors of atr kinase
|
|
US8841449B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
EP2776422A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013071093A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of atr kinase
|
|
EP2776421A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2776429A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US9567328B2
(en)
|
2011-12-21 |
2017-02-14 |
Allergan, Inc. |
Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
|
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
|
US20140044802A1
(en)
|
2012-04-05 |
2014-02-13 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
and combination therapies thereof
|
|
ME03573B
(me)
|
2012-05-04 |
2020-07-20 |
Samumed Llc |
1H-PIRAZOLO[3,4-B]PIRIDINI l NJIHOVA TERAPEUTSKA UPOTREBA
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
DK2904406T3
(en)
|
2012-10-04 |
2018-06-18 |
Vertex Pharma |
METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
|
|
MX2015004615A
(es)
*
|
2012-10-16 |
2015-07-17 |
Hoffmann La Roche |
Inhibidores de serina/treonina cinasa.
|
|
US8912198B2
(en)
|
2012-10-16 |
2014-12-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
SMT202000713T1
(it)
|
2012-12-07 |
2021-03-15 |
Vertex Pharma |
Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
|
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
CN105120862A
(zh)
|
2013-01-08 |
2015-12-02 |
萨穆梅德有限公司 |
Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用
|
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
|
US9206188B2
(en)
*
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
CN105683182A
(zh)
|
2013-08-30 |
2016-06-15 |
埃姆比特生物科学公司 |
联芳基乙酰胺化合物及其使用方法
|
|
HUE046727T2
(hu)
|
2013-12-06 |
2020-03-30 |
Vertex Pharma |
Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
|
|
CN103980272B
(zh)
*
|
2014-04-18 |
2016-02-17 |
海门瑞一医药科技有限公司 |
一种合成5-氰基-1H-吡唑并[3,4-b]吡啶的方法
|
|
CN107074863B
(zh)
|
2014-06-05 |
2019-12-03 |
沃泰克斯药物股份有限公司 |
Atr激酶抑制剂的制备方法及其不同的固体形式
|
|
PL3157566T3
(pl)
|
2014-06-17 |
2019-10-31 |
Vertex Pharma |
Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
|
|
WO2016040182A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
|
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
|
WO2016040188A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
|
US10160755B2
(en)
|
2015-04-08 |
2018-12-25 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
CA2992945A1
(en)
|
2015-07-17 |
2017-01-26 |
Memorial Sloan-Kettering Cancer Center |
Combination therapy using pdk1 and pi3k inhibitors
|
|
US10206908B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
|
US10463651B2
(en)
|
2015-08-03 |
2019-11-05 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
|
|
WO2017023993A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
US10226448B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
|
|
WO2017023989A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023980A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
US10350199B2
(en)
|
2015-08-03 |
2019-07-16 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
WO2017024003A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023988A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
US10285983B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
|
|
US10195185B2
(en)
|
2015-08-03 |
2019-02-05 |
Samumed, Llc |
3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
US10383861B2
(en)
|
2015-08-03 |
2019-08-20 |
Sammumed, LLC |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
|
WO2017024015A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
US10519169B2
(en)
|
2015-08-03 |
2019-12-31 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
WO2017024004A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017024026A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
US10604512B2
(en)
|
2015-08-03 |
2020-03-31 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
|
|
KR102678021B1
(ko)
|
2015-09-30 |
2024-06-26 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
|
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US12365689B2
(en)
|
2015-10-16 |
2025-07-22 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
SG10201913999PA
(en)
|
2015-10-16 |
2020-03-30 |
Abbvie Inc |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
|
CN108473491A
(zh)
|
2015-11-06 |
2018-08-31 |
萨穆梅德有限公司 |
2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途
|
|
AR108325A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
DK3464285T3
(da)
|
2016-06-01 |
2022-12-19 |
Biosplice Therapeutics Inc |
Fremgangsmåde til fremstilling af n-(5-(3-(7-(3-fluorphenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamid
|
|
EP3528808B1
(en)
|
2016-10-21 |
2021-10-06 |
BioSplice Therapeutics, Inc. |
Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
|
|
MA46696A
(fr)
|
2016-11-07 |
2019-09-11 |
Samumed Llc |
Formulations injectables à dose unique prêtes à l'emploi
|
|
US11331313B2
(en)
|
2017-05-22 |
2022-05-17 |
Whitehead Institute For Biomedical Research |
KCC2 expression enhancing compounds and uses thereof
|
|
KR20200131246A
(ko)
|
2018-02-15 |
2020-11-23 |
누베이션 바이오 인크. |
키나제 억제제로서의 헤테로시클릭 화합물
|
|
KR102108414B1
(ko)
*
|
2018-11-21 |
2020-05-11 |
중앙대학교 산학협력단 |
Aurka 매개 kdm6b 활성 조절을 통한 암세포 분화 조절 용도
|
|
TWI848141B
(zh)
*
|
2019-07-04 |
2024-07-11 |
英屬開曼群島商百濟神州有限公司 |
及其用途
|
|
CN112239473B
(zh)
|
2019-07-17 |
2023-12-08 |
百济神州(北京)生物科技有限公司 |
作为hpk1抑制剂的三环化合物的制备方法
|
|
EP4013753A1
(en)
*
|
2019-08-14 |
2022-06-22 |
Nuvation Bio Inc. |
Heterocyclic compounds as kinase inhibitors
|
|
CN121758442A
(zh)
*
|
2021-07-07 |
2026-03-31 |
南方科技大学 |
含氮杂环化合物及其制备方法、药物组合物和应用
|
|
CN118834206A
(zh)
*
|
2023-04-24 |
2024-10-25 |
北京宇繁科技有限责任公司 |
一种map4k4抑制剂及其制备方法和应用
|